Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

OBJECTIVES The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas. Because these elevations may precede clinical detection by a year or more, CA 125 is potentially useful for early detection as part of an ovarian cancer screening program. However, CA 125 is often not elevated in clinically detected cancer and is frequently elevated in women with benign ovarian tumors. CA 125 may be more useful in conjunction with one or more other tumor biomarkers. Additional markers could play a role if, when used with CA 125, they identify some carcinomas missed by CA 125 (i.e., they improve sensitivity), rule out false positives (i.e., improve specificity), or are able to detect the same cancers earlier. METHODS We have evaluated a composite marker (CM) that combines CA 125 and a previously described soluble mesothelin related (SMR) marker in sera from 52 ovarian cancer cases, 43 controls with benign ovarian tumors, and 220 normal risk controls who participated in a screening program, including 25 healthy women having two serum samples collected 1 year apart. CA 125, SMR, and CM were evaluated for their ability to identify clinical disease and for their temporal stability, which assesses their ability to obtain even greater sensitivity when used in a longitudinal screening program. RESULTS CM has the best sensitivity, with specificity equal to CA 125. Importantly, CM has temporal stability at least as high as CA 125. CONCLUSION The CM may outperform CA 125 alone in a longitudinal screening program as well as in a diagnostic setting.

[1]  M R Conaway,et al.  Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. , 1995, Gynecologic oncology.

[2]  N. Urban,et al.  A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. , 2003, Biostatistics.

[3]  D. Singer,et al.  Quantifying the potential benefit of CA 125 screening for ovarian cancer. , 1991, Journal of clinical epidemiology.

[4]  D. Pauler,et al.  Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers , 2001 .

[5]  R. Bast,et al.  An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. , 1988, Gynecologic oncology.

[6]  R. Bast,et al.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers , 1995, Cancer.

[7]  R. Bast,et al.  Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. , 1999, Gynecologic oncology.

[8]  N. Yamaguchi,et al.  Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*) , 1995, The Journal of Biological Chemistry.

[9]  Nicole Urban,et al.  Generating longitudinal screening algorithms using novel biomarkers for disease. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  I. Pastan,et al.  Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR‐3) cell line , 1994, International journal of cancer.

[11]  Z. Ye,et al.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Margaret Sullivan Pepe,et al.  Combining Several Screening Tests: Optimality of the Risk Score , 2002, Biometrics.

[13]  Kathleen A. Cronin,et al.  Changepoint Modeling of Longitudinal PSA as a Biomarker for Prostate Cancer , 1997 .

[14]  Ian J. Jacobs,et al.  SCREENING FOR OVARIAN CANCER : A PILOT RANDOMISED CONTROLLED TRIAL , 1999 .

[15]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[16]  O. Valenta,et al.  Gynecologic oncology , 1990 .

[17]  R. Bast,et al.  Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer , 1986, Obstetrics and gynecology.

[18]  R. Bast,et al.  Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer , 1992, Obstetrics and gynecology.

[19]  Peter E. Rossi,et al.  Case Studies in Bayesian Statistics , 1998 .

[20]  I. Pastan,et al.  Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. , 1992, Cancer research.

[21]  B. Karlan,et al.  Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  U Menon,et al.  Factors influencing serum CA125II levels in healthy postmenopausal women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.